Breast Cancer Research and Treatment

, Volume 108, Issue 3, pp 319–331 | Cite as

Gemcitabine in the management of metastatic breast cancer: a systematic review

Review

Abstract

Background

A systematic review of the evidence for gemcitabine chemotherapy, alone or in combination, in women with metastatic/advanced breast cancer was undertaken in order to determine gemcitabine’s role in the first-line and/or second-line or greater setting.

Methods

MEDLINE, EMBASE, the American Society of Clinical Oncologists, San Antonio Breast Cancer Symposium proceedings, and the Cochrane Library were searched through September 2006 for randomized controlled trials and non-randomized phase two trials.

Results

Eighty-three trials were identified, including four randomized phase III trials. All of the phase III trials included first-line patients. Two of the phase III trails demonstrated clinical benefit with gemcitabine-based chemotherapy in terms of superior efficacy or less toxicity while two phase III trials found no clinical benefit based on less efficacy or increased toxicity. Although 78 phase II trials of gemcitabine alone or in combination with other chemotherapy agents were identified, few combinations showed results compelling enough to warrant randomized trials.

Conclusion

Available data do not support the acceptance of gemcitabine as a standard therapeutic option in women with metastatic breast cancer in the third-line or greater setting, nor should it be considered as first-line therapy in anthracycline naïve women. Gemcitabine appears to be most effective when administered with a taxane (docetaxel/paclitaxel) in the first- or second-line setting, with gemcitabine/taxane combinations representing a viable alternative to currently accepted taxane combinations such as capecitabine/docetaxel. There is no evidence at this time to support the use of gemcitabine triplets, given the equal efficacy to anthracycline triplets and the added toxicity.

Keywords

Metastatic breast cancer Gemcitabine Chemotherapy Systematic review 

References

  1. 1.
    Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination therapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8):1431–1439PubMedCrossRefGoogle Scholar
  2. 2.
    Henderson IC, Berry DA, Demetri GD, Cirrincione C, Goldstein LJ, Martion S et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976–983PubMedCrossRefGoogle Scholar
  3. 3.
    Roche H, Fumoleau P, Spielmann M, et al (2005) Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs. 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment node positive cancer. Breast Cancer Res Treat 88(Suppl 1):S16, A27Google Scholar
  4. 4.
    Martin M, Pienkowski T, Mackey J, Pawlicki M, Gustalla JP, Weaver C et al (2005) Adjuvant docetaxel for node-positive breast cancer. New Engl J Med 352:2302–2313PubMedCrossRefGoogle Scholar
  5. 5.
    Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Lluch A et al (2005) Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study [slides on the internet] [abstract 581]. In: 2005 ASCO Annual Meeting. Available from: http://www.asco.org/portal/site/ASCO.. Cited 16 Sep 2005
  6. 6.
    Chan S, Romieu G, Huober J, et al (2005) Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. J Clin Oncol 23(16 Suppl):A581Google Scholar
  7. 7.
    O’Shaughnessy J, Nag S, Calderillo-Ruiz G et al (2003) Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study. Proc Am Soc Clin Onc 22:7, A25Google Scholar
  8. 8.
    O’Shaughnessy J, Nag S, Calderillo-Ruiz G, Jordaan J, Llombart A, Pluzanska A et al (2003) Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study [slides on the Internet] [abstract 25]. In: 2003 ASCO Annual Meeting. Available from: http://www.asco.org/portal/site/ASCO. Cited 11 May 2005
  9. 9.
    Moinpour C, Wu J, Donaldson G, et al (2004) Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): quality of life (QoL) and pain palliation results from the global phase III study. J Clin Oncol 22(14 Suppl):A621Google Scholar
  10. 10.
    Moinpour C, Wu J, Donaldson G, Liepa A, Melemed A, Oshaughnessy J et al (2004) Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): quality of life (QoL) and pain palliation results from the global phase III study [slides on the Internet] [abstract 621]. In: 2004 ASCO Annual Meeting. Available from: http://www.asco.org/portal/site/ASCO. Cited 11 May 2005
  11. 11.
    Albain KS, Nag S, Calderillo-Ruiz G et al (2004) Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. J Clin Oncol 22(14 Suppl):A510Google Scholar
  12. 12.
    Albain KS, Nag S, Calderillo-Ruiz G, Jordaan JP, Llombart A, Pluzanska A et al (2004) Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival [slides on the Internet] [abstract 510]. In: 2004 ASCO Annual Meeting. Available from: http://www.asco.org/portal/site/ASCO. Cited 11 May 2005.
  13. 13.
    Feher O, Vodvarka P, Jassem J, Morack G, Advani SH, Khoo K et al (2005) First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol 16:899–908PubMedCrossRefGoogle Scholar
  14. 14.
    Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z et al (2005) Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group international, multicenter, prospective, randomized phase III trial. J Clin Oncol 23(7):1401–1408PubMedCrossRefGoogle Scholar
  15. 15.
    Khoo KS, Zaidi SHM, Srimuninnimit V, Song S, Nair R, Ngelangel CA et al (2006) Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study. Eur J Cancer 42:1797–1806PubMedCrossRefGoogle Scholar
  16. 16.
    Chan S (2005) Gemcitabine plus docetaxel versus capecitabine plus docetaxel for patients with anthracycline-pretreated metastatic breast cancer: a review of the results of a European phase III trial. EJC Supplements 3(5):17–21Google Scholar
  17. 17.
    Levy C, Fumoleau P (2005) Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients? Cancer Treat Rev 31(Suppl 4):S17–S22PubMedCrossRefGoogle Scholar
  18. 18.
    Fumoleau P, Romieu G, Chan S et al (2006) Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs. capecitabine plus docetaxel in metastatic breast cancer. J Clin Oncol 24(18S):A682Google Scholar
  19. 19.
    Fumoleau P, Romieu G, Chan S, Hueber J, Tubiana-Hulin M, Schneeweiss A et al (2006) Impact of symptoms and toxicity on quality of life (QoL): exploratory analysis of gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) in metastatic breast cancer (MBC) [slides on the Internet] [abstract 682]. In: 2006 ASCO Annual Meeting. Available from: http://www.asco.org/portal/site/ASCO. Cited 01 Oct 2006
  20. 20.
    Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A (2002) Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62(1):2–8PubMedCrossRefGoogle Scholar
  21. 21.
    Possinger K, Kaufmann M, Coleman R, Stuart NSA, Helsing M, Ohnmacht U, et al (1999) Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10(2):155–162PubMedCrossRefGoogle Scholar
  22. 22.
    Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J et al (1995) Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13(11):2731–2736PubMedGoogle Scholar
  23. 23.
    Schmid P, Akrivakis K, Flath B, Grosse Y, Sezer O, Mergenthaler HG et al (1999) Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 10(7):625–631PubMedCrossRefGoogle Scholar
  24. 24.
    El Serafy M, El Kohdary A, El Zawahry H et al (2003) Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Onc 22:50 [A199]Google Scholar
  25. 25.
    Perez-Manga G, Lluch A, Alba E, Moreno-Nogueira JA, Palomero M, Garcia-Conde J et al (2000) Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J Clin Oncol 18(13):2545–2552PubMedGoogle Scholar
  26. 26.
    Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K et al (2003) Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21(17):3249–3254PubMedCrossRefGoogle Scholar
  27. 27.
    Fabi A, Papaldo P, Ciccarese M et al (2004) Pegylated liposomal doxorubicin (PLD) and gemcitabine (G) in metastatic breast cancer (MBC) patients: a phase II study. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A813Google Scholar
  28. 28.
    Campone M, Viens P, Dieras V et al (2001) Gemzar (G) and epirubicin (E) in patients (pts) with metastatic breast cancer (MBC): results of a phase II trial [abstract]. Proc Am Soc Clin Onc 20(2):48b [A1940]Google Scholar
  29. 29.
    Hausmaninger H, Morack G, Heinrich B, Wallwiener D, Hoffken K, Buksmaui S et al (2004) Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study. Am J Clin Oncol 27(4):429–435PubMedCrossRefGoogle Scholar
  30. 30.
    Kornek GV, Haider K, Kwasny W, Raderer M, Schull B, Payrits T et al (2002) Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res 8:1051–1056PubMedGoogle Scholar
  31. 31.
    Garle PA, Calvo L, Mayordomo JI et al (2003) Gemcitabine and docetaxel given every other week as first-line therapy for metastatic breast cancer (MBC): Final results of a phase II study conducted within the Breast Cancer Investigation Spanish Group (GEICAM). Proc Am Soc Clin Onc 22:50 [A201]Google Scholar
  32. 32.
    Palmeri S, Vaglica M, Spada S, Filippelli G, Farris A, Palmeri L et al (2005) Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study. Oncology 68:438–445PubMedCrossRefGoogle Scholar
  33. 33.
    Mavroudis D, Malamos N, Polyzos A, Kouroussis C, Christophilakis Ch, Varthalitis I et al (2004) Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study. Oncology 67:250–256PubMedCrossRefGoogle Scholar
  34. 34.
    Fountzilas G, Nicolaides C, Bafaloukos D, Kalogera-Fountzila A, Kalofonos H, Samelis G et al (2000) Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. Cancer Invest 18(6):503–509PubMedCrossRefGoogle Scholar
  35. 35.
    Laufman LR, Spiridonidis CH, Pritchard J, Roach R, Zangmeister J, Larrimer N et al (2001) Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial. Ann Oncol 12(9):1259–1264PubMedCrossRefGoogle Scholar
  36. 36.
    Genot J, Tubiana-Hulin M, Tubiana-Mathieu M et al (2002) Gemcitabine and paclitaxel in metastatic breast cancer: a phase II study in the first line setting [abstract]. Proc Am Soc Clin Onc 21(2):48b [A2002]Google Scholar
  37. 37.
    Delfino C, Caccia G, Gonzales LR, Mickiewicz E, Rodger J, Balbiani L, et al (2004) Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer. Oncology 66(1):18–23PubMedCrossRefGoogle Scholar
  38. 38.
    Colomer R, Llombart-Cussac A, Lluch A, Barnadas A, Ojeda B, Caranana V et al (2004) Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain. Ann Oncol 15(2):201–206PubMedCrossRefGoogle Scholar
  39. 39.
    Alauddin Z, Shaharyar A (2005) Gemcitabine and cisplatin combination chemotherapy as first-line treatment in patients with metastatic breast cancer. J Clin Oncol 23(16 Suppl):A713Google Scholar
  40. 40.
    Ruiz GC, de la Pena HF, Meza FA et al (2001) A phase II study of gemcitabine plus cisplatin in metastatic breast cancer (MBC). Proc Am Soc Clin Onc 20:A1988Google Scholar
  41. 41.
    Xu B, Li K, Liu D (2003) Phase II trial of gemcitabine and cisplatin in anthracycline-resistant metastatic breast cancer. Proc Am Soc Clin Onc 22:53 [A211]Google Scholar
  42. 42.
    Burch PA, Mailliard JA, Hillman DW, Perez EA, Krook JE, Rowland KM, et al (2005) Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group trial. Am J Clin Oncol 28(2):195–200PubMedCrossRefGoogle Scholar
  43. 43.
    Haider K, Kornek GV, Kwasny W, Weinlander G, Valencak J, Lang F et al (1999) Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor. Breast Cancer Res Treat 55(3):203–211PubMedCrossRefGoogle Scholar
  44. 44.
    Gennatas C, Mouratidou D, Tsavaris N et al (2005) Gemcitabine in combination with vinorelbine for heavily pretreated advanced breast cancer. J Clin Oncol 23(16 Suppl):A741Google Scholar
  45. 45.
    Valenza R, Leonardi V, Gebbia V, Agostara B (2000) Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study. Ann Oncol 11(4):495–496PubMedCrossRefGoogle Scholar
  46. 46.
    Sanal SM, Gokmen E, Karabulut B, Sezgin C (2002) Gemcitabine and vinorelbine combination in patients with metastatic breast cancer. Breast J 8(3):171–176PubMedCrossRefGoogle Scholar
  47. 47.
    Mariani G, Tagliabue P, Zucchinelli P, Brambilla C, Demicheli R, Villa E et al (2001) Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer. Breast Cancer Res Treat 70:163–169PubMedCrossRefGoogle Scholar
  48. 48.
    Lobo F, Virizuela JA, Dorta FJ, Florian J, Lomas M, Jimenez E et al (2003) Gemcitabine/vinorelbine in metastatic breast cancer patients previously treated with anthracyclines: results of a phase II trial. Clin Breast Cancer 4(1):46–50PubMedGoogle Scholar
  49. 49.
    Graham DL, Hillman DW, Hobday TJ et al (2005) N0234: phase II study of erlotinib (OSI-774) plus gemcitabine as first- or second-line therapy for metastatic breast cancer (MBC). J Clin Oncol 23(16 Suppl):A644Google Scholar
  50. 50.
    Ma CX, Steen P, Rowland KM et al (2004) A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): an NCCTG study. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A639Google Scholar
  51. 51.
    Cappuzzo F, Mazzoni F, Gennari A, Donati S, Salvadori B, Orlandini C et al (2004) Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. Br J Cancer 90(1):31–35PubMedCrossRefGoogle Scholar
  52. 52.
    Conte PF, Gennari A, Donati S, Salvadori B, Baldini E, Bengala C et al (2001) Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast Cancer Res Treat 68(2):171–179PubMedCrossRefGoogle Scholar
  53. 53.
    Sanchez-Rovira P, Jaen A, Gonzalez E, Porras I, Duenas R et al (2001) Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial. Oncology (Huntingt) 15(2 Suppl 3):44–47Google Scholar
  54. 54.
    Levin M, Durgam S, Novetsky A (2002) Cyclophosphamide, doxorubicin, and gemcitabine combination chemotherapy for treatment of metastatic and locally advanced breast cancer. Cancer Invest 20(7–8):872–875PubMedCrossRefGoogle Scholar
  55. 55.
    Colomer R, Mayordomo JI, Calvo I et al (2004) HER2 ECD-positive metastatic breast cancer treated with gemcitabine, paclitaxel plus trastuzumab (GTH). Breast Cancer Res Treat 88 Suppl 1:A3046Google Scholar
  56. 56.
    Fountzilas G, Christodoulou C, Tsavaridis D, Kalogera-Fountzila A, Aravantinos G, Razis E et al (2004) Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer Invest 22(5):655–662PubMedCrossRefGoogle Scholar
  57. 57.
    Sledge GW Jr (2003) Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Huntingt) 17(12 Suppl 14):33–35Google Scholar
  58. 58.
    Polyzos A, Mavroudis D, Boukovinas J et al (2004) A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER-2. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed)(14 Suppl):A728Google Scholar
  59. 59.
    Mulkerin D, Dietrich L, Koch P et al (2001) A phase II study of Gemcitabine, 5-Fluorouracil, and Leucovorin in Women with Metastatic Breast Cancer (MBC). Proc Am Soc Clin Onc 20(2):43b [A1919]Google Scholar
  60. 60.
    Rha SY, Moon YH, Jeung HC, Kim YT, Sohn JH, Yang WI et al (2005) Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 90:215–221PubMedCrossRefGoogle Scholar
  61. 61.
    Smorenburg CH, Bontenbal M, Seynaeve C, van Zuylen C, de Heus G, Verweij J et al (2001) Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 66(1):83–87PubMedCrossRefGoogle Scholar
  62. 62.
    Brodowicz T, Kostler WJ, Moslinger R, Tomek S, Vaclavik I, Herscovici V et al (2000) Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast 9(6):338–342PubMedCrossRefGoogle Scholar
  63. 63.
    Gerson R, Serrano-O A, Villalobos A et al (2000) Gemcitabine response in advanced breast cancer in relation to immunohistochemical factors. Proc Am Soc Clin Onc 19(1):145a [A572]Google Scholar
  64. 64.
    Spielmann M, Llombart-Cussac A, Kalla S, Espie M, Namer M, Ferrero JM et al (2001) Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60(4):303–307PubMedCrossRefGoogle Scholar
  65. 65.
    Valerio MR, Cicero G, Armata MG et al (2001) Gemcitabine (G) in pretreated breast cancer (BC). Proc Am Soc Clin Onc 20(2):51b [A1953]Google Scholar
  66. 66.
    Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M et al (2005) A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer 6(1):55–60PubMedGoogle Scholar
  67. 67.
    Haider K, Kornek G, Kwasny W et al (2004) Multicenter phase II trial of gemcitabine plus liposomal doxorubicin in chemotherapeutically pretreated patients with advanced breast cancer (ABC). J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A696Google Scholar
  68. 68.
    Mavroudis D, Malamos N, Alexopoulos A, Kourousis C, Agelaki S, Sarra E et al (1999) Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. Ann Oncol 10(2):211–215PubMedCrossRefGoogle Scholar
  69. 69.
    Brandi M, Vici P, Lopez M, Valerio MR, Giotta F, Gebbia N et al (2004) Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study. Semin Oncol 31(2 Suppl 5):13–19PubMedCrossRefGoogle Scholar
  70. 70.
    Alexopoulos A, Tryfonopoulos D, Karamouzis MV, Gerasimidis G, Karydas I, Kandilis K et al (2004) Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. Ann Oncol 15:95–99PubMedCrossRefGoogle Scholar
  71. 71.
    Khoo KS, Zaidi M, Srimuninnimit V et al (2004) Randomized phase II trial of three gemcitabine (GEM)-taxane combinations in metastatic breast cancer (MBC). J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A710Google Scholar
  72. 72.
    Murad AM (2003) Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer. Oncology (Huntingt) 17(12 Suppl 14):26–32Google Scholar
  73. 73.
    Catania C, Nole F, Balduzzi A, et al (2004) Caring for heavily pretreated patients with metastatic breast cancer (MBC): Carboplatin (CBDCA) – gemcitabine (GCB) combination is effective and well tolerated. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A724Google Scholar
  74. 74.
    Silva JA, Perez Michel LM, Gallardo Rincon D (2004) Gemcitabine plus carboplatin in recurrent and advanced breast cancer: a phase II trial. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A877Google Scholar
  75. 75.
    Nagourney RA, Link J, Sommers B, et al (2004) Carboplatin & gemcitabine repeating doublet in recurrent breast cancer. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A851Google Scholar
  76. 76.
    Nasr FL, Chahine GY, Kattan JG, Farhat FS, Mokaddem WT, Tueni EA, et al (2004) Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer. Clin Breast Cancer 5(2):117–22PubMedGoogle Scholar
  77. 77.
    Latini L, Torresi U, Valeri M, et al (2003) Carboplatin-gemcitabine combination in anthracyclines- and/or taxanes-resistant metastatic breast cancer. Proc Am Soc Clin Onc 22:80 [A318]Google Scholar
  78. 78.
    Alés-Martinez JE, Hernández R, Sánchez-Escribano R, et al (2005) Tailored low-dose gemcitabine-cisplatin combination is a feasible and effective treatment in heavily pretreated advanced breast cancer patients. J Clin Oncol 23(16 Suppl):A837Google Scholar
  79. 79.
    Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS (2000) Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 18(11):2245–9PubMedGoogle Scholar
  80. 80.
    Chaudhry S, Abdel-Rahman H, Patil R et al (2000) Prospective phase II study of weekly cisplatin-gemcitabine in refractory metastatic breast cancer (RM-BC). Proc Am Soc Clin Onc 19(1):111a [A430]Google Scholar
  81. 81.
    Stemmler J, Wohlrab B, Bosse D, et al (2003) Gemcitabine plus cisplatin in intensively pretreated metastatic breast cancer: A phase II trial. Proc Am Soc Clin Onc 22:73 [A291]Google Scholar
  82. 82.
    Fuentes de la Pena H, Tellez E, Bastarrachea J, et al (2001) Gemcitabine plus cisplatin as a palliative treatment in metastatic or refractory breast cancer (MRBC). Proc Am Soc Clin Onc 20(2):60b [A1990]Google Scholar
  83. 83.
    Alauddin Z, Fcps S, Rehman E et al (2003) Gemcitabine and cisplatin combination chemotherapy as second-line treatment in patients with metastatic breast cancer. Proc Am Soc Clin Onc 22:53 [A212]Google Scholar
  84. 84.
    Ajarim D, Ezzat A, Bazarbashi S, et al (2004) Gemcitabine plus cisplatin combination as second-line treatment in patients with metastatic breast cancer (MBC). J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A774Google Scholar
  85. 85.
    Schmid P, Heilmann V, Schulz CO, et al (2005) Gemcitabine as prolonged infusion and vinorelbine as second-line therapy in metastatic breast cancer: results of a phase-II-study. Breast Cancer Res Treat 88 Suppl 1:A5064Google Scholar
  86. 86.
    Zavettieri M, Raffaele M, Azzarello D et al (2003) Phase II study of vinorelbine (V) and gemcitabine (G) in metastatic breast cancer (MBC) patients, previously treated with anthracyclines and /or taxanes. Proc Am Soc Clin Onc 22:64 [A256]Google Scholar
  87. 87.
    Stathopoulos GP, Rigatos SK, Pergantas N, Tsavdarides D, Athanasiadis I, Malamos NA, et al (2002) Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Oncol 20(1):37–41PubMedCrossRefGoogle Scholar
  88. 88.
    Rossi E, Perrone F, Labonia V, Landi G, Nuzzo F, Amabile G et al (2003) Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? a single-center phase 2 study. Oncology 64(4):479–480PubMedCrossRefGoogle Scholar
  89. 89.
    Nicolaides C, Dimopoulos MA, Samantas E, Bafaloukos D, Kalofonos C, Fountzilas G et al (2000) Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 11(7):873–875PubMedCrossRefGoogle Scholar
  90. 90.
    Morabito A, Filippelli G, Palmeri S, Cascinu S, Ferrau F, Zagonel V et al (2003) The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study. Breast Cancer Res Treat 78(1):29–36PubMedCrossRefGoogle Scholar
  91. 91.
    Donadio M, Ardine M, Berruti A, Ritorto G, Fea E, Mistrangelo M, et al (2003) Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol 52(2):147–52PubMedCrossRefGoogle Scholar
  92. 92.
    Morabito A, Carillio G, Bonginelli P, et al (2004) Gemcitabine, vinorelbine and trastuzumab combination (GemVinT) as second-third line therapy for HER-2 overexpressing metastatic breast cancer (MBC). J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A759Google Scholar
  93. 93.
    O’Shaughnessy J, Vukelja SJ, Marsland T, Kimmel G, Ratnam S, Pippen J (2004) Phase II trial of gemcitabine plus trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 5(2):142–7PubMedGoogle Scholar
  94. 94.
    Christodoulou C, Fountzilas G, Razi E, et al (2003) Gemcitabine and trastuzumab combination as salvage treatment in patients with HER 2-positive metastatic breast cancer. Proc Am Soc Clin Onc 22:42, A166Google Scholar
  95. 95.
    Salman HS, Tanaka K, Sparano JA (2002) Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes. Clin Breast Cancer 2(4):299–303PubMedCrossRefGoogle Scholar
  96. 96.
    Ahn J, Kim J, Lee J et al (2005) Phase II study of gemcitabine and capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. J Clin Oncol 23(16 Suppl):A895Google Scholar
  97. 97.
    Andres R, Mayordomo JI, Polo E et al (2003) Activity of gemcitabine plus capecitabine in patients with metastatic breast cancer refractory to anthracyclines and taxanes. Breast Cancer Res Treat 82 Suppl 1:A360Google Scholar
  98. 98.
    Pérez-Manga G, López-Criado P, Méndez M, et al (2004) Gemcitabine (G) plus capecitabine (C) in previously treated metastatic breast cancer (MBC) patients. Final results from a phase II GOTI trial. Breast Cancer Res Treat 88 Suppl 1:A5063Google Scholar
  99. 99.
    Agelaki S, Karyda E, Kouroussis C, Ardavanis A, Kalbakis K, Malas K (2003) Gemcitabine plus irinotecan in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study. Oncology 64(4):477–8PubMedCrossRefGoogle Scholar
  100. 100.
    Onyenadum A, Kosmidis P, Aravantinos G, et al (2004) Mitoxantrone plus gemcitabine in pretreated patients with advanced breast cancer. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A829Google Scholar
  101. 101.
    Lorusso V, Crucitta E, Silvestris N, Catino A, Caporusso L, Mazzei A, et al (2003) Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. Br J Cancer 88(4):491–5PubMedCrossRefGoogle Scholar
  102. 102.
    Frasci G, D’Aiuto G, Comella P, Thomas R, Capasso I, Botti G, et al (2002) A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients. Oncology 62(1):25–32PubMedCrossRefGoogle Scholar
  103. 103.
    Stanculeanu DL, Cringeanu A, Minea LN, et al (2004) Treatment of metastatic breast cancer with alternative vinorelbine and gemcitabine. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A800Google Scholar
  104. 104.
    PDQ [database on the Internet] (2006 Oct 04) Phase III study of two different schedules (weekly and tri-weekly) of combination of gemcitabine and two taxanes in MBC. In: Bethesda (MD): National Cancer Institute. Available from: http://www.cancer.gov/Search/SearchClinicalTrialsAdvanced.asp. Cited 04 Oct 2006
  105. 105.
    PDQ [database on the Internet] (2006 Oct 04) Docetaxel vs. docetaxel-gemcitabine in breast cancer. In: Bethesda (MD): National Cancer Institute. Available from:http://www.cancer.gov/Search/SearchClinicalTrialsAdvanced.aspx. Cited 04 Oct 2006
  106. 106.
    PDQ [database on the Internet] (2006 Oct 04) Study comparing concomitant docetaxel + gemcitabine to sequential therapy of docetaxel followed by gemcitabine. In: Bethesda (MD): National Cancer Institute. Available from: http://www.cancer.gov/Search/SearchClinicalTrialsAdvanced.asp. Cited 04 Oct 2006
  107. 107.
    Mavroudis D, Ardavanis A, Boukovinas I et al (2006) A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. J Clin Oncol 24(18S):A658Google Scholar
  108. 108.
    O’Shaughnessy J, Miles DW, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12):2812–2823PubMedCrossRefGoogle Scholar
  109. 109.
    Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E et al (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23(24):5542–5551PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.The Ottawa Hospital Regional Cancer CentreOttawaCanada
  2. 2.Toronto-Sunnybrook Regional Cancer CenterTorontoCanada
  3. 3.McMaster UniversityHamiltonCanada

Personalised recommendations